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Antimicrobial Susceptibility Testing of Haemophilus influenzae,
Branhamella catarrhalis, and Neisseria gonorrhoeae
GARY V. DOERNl* AND RONALD N. JONES2
University of Massachusetts Medical Center, Worcester, Massachusetts 01655,' and The Clinical Microbiology Institute,
Tualatin, Oregon 970622
INTRODUCTION
During the last two decades, resistance to selected anti-
microbial agents commonly used to treat infections caused
by Haemophilus influenzae and Neisseria gonorrhoeae has
become increasingly prevalent. In addition, during the last
10 years, information has accumulated which supports the
role of Branhamella catarrhalis as the etiologic agent of a
variety of human infections. It is now clear that most clinical
isolates of B. catarrhalis produce 3-lactamase and are,
therefore, possibly not susceptible to beta-lactam antimicro-
bial agents such as penicillin, ampicillin, and amoxicillin,
agents often considered the drugs of choice for treating
infections such as those with which B. catarrhalis is often
associated. The recognition of antimicrobial resistance
among these three organisms has led to a need for in vitro
susceptibility test procedures and interpretive criteria for the
results which reliably predict therapeutic outcome. Because
of the fastidious nature of these three organisms, suscepti-
bility testing procedures which effectively assess the in vitro
activity of antimicrobial agents for rapidly growing bacteria
are of questionable value. The intent of this review is to
provide specific recommendations for in vitro susceptibility
testing of H. influenzae, B. catarrhalis, and N. gonorrhoeae.
H. INFLUENZAE
Susceptibility test methods. The results of qualitative and
quantitative susceptibility test methods with H. influenzae
are clearly influenced by the composition of the test medium
(5, 44, 68). Numerous different media have been advocated
for use when testing this organism (52). Until recently, the
National Committee for Clinical Laboratory Standards
(NCCLS) has recommended that chocolate Mueller-Hinton
agar (i.e., Mueller-Hinton agar supplemented with 1% bo-
vine hemoglobin and a source of V-factor) be used to
perform disk diffusion susceptibility tests with H. influenzae
(50). Zone diameter interpretive criteria have been defined
for ampicillin, chloramphenicol, amoxicillin-clavulanate,
and ampicillin-sulbactam (50). The medium recommended
for broth dilution tests consists of cation-adjusted Mueller-
Hinton broth supplemented with 3 to 5% lysed horse blood
and a source of V-factor (51). MIC interpretive criteria have
been developed for the same four antimicrobial agents
mentioned above (51).
Recently, extensive studies performed by Jorgensen and
colleagues have led to the development of an alternative
medium for performing both disk diffusion and broth dilution
susceptibility tests with H. influenzae (37, 38). This medium
* Corresponding author.
has been referred to as haemophilus test medium (HTM). In
its agar form, HTM consists of Mueller-Hinton agar, 15 ,ug of
purified bovine hematin per ml, 15 pLg of NAD per ml, and 5
mg of yeast extract per [LI. The broth version is essentially
the same, except that cation-adjusted Mueller-Hinton broth
is used instead of Mueller-Hinton agar and the medium is
supplemented with thymidine phosphorylase (0.2 IU/ml) in
addition to hematin, NAD, and yeast extract.
The advantages of HTM in comparison with other media
advocated for susceptibility tests with Haemophilus species
include its optical clarity, its stability, its utility for testing
trimethoprim and sulfonamide antimicrobial agents, the re-
producibility of test results, and the fact that it soon will be
commercially available in both its broth and agar forms
(J. H. Jorgensen, personal communication).
A recent three-center collaborative study (G. V. Doern,
J. H. Jorgensen, and C. Thornsberry, manuscript in prepa-
ration) was conducted to define the optimum conditions for
performing susceptibility tests with H. influenzae using
HTM, as well as to develop both zone diameter and MIC
interpretive criteria. The results of this study serve as the
basis for the following recommendations regarding suscep-
tibility tests with Haemophilus species.
The following procedure is advocated for disk diffusion
susceptibility tests. Colony growth from an overnight choc-
olate agar culture is suspended in Mueller-Hinton broth to a
turbidity equivalent to a 0.5 McFarland standard by using a
photometric device. This suspension is used to confluently
inoculate the surface of an HTM agar plate. Antimicrobial
disks are applied, and the plate is incubated for 16 to 18 h at
35°C in 5 to 7% CO2 before zones of inhibition are measured.
Zone diameter interpretive criteria and MIC correlates have
been developed for 18 antimicrobial agents with HTM by
using this method (Table 1). These interpretive criteria will
serve as the basis for revised NCCLS recommendations
regarding disk diffusion susceptibility tests with Haemophi-
lus species (National Committee for Clinical Laboratory
Standards, Tentative Standard M2-T4, in press).
Determinations of MICs with HTM are best accomplished
by using a microdilution format with 100 ,ud as the final broth
volume. A suspension of test organism equivalent to a 0.5
McFarland standard is prepared as described above for the
disk diffusion procedure. Appropriate dilutions of this sus-
pension are made, and the wells of a microdilution tray are
inoculated so as to achieve a final organism concentration of
5 x 105 CFU/ml. Trays are incubated for 20 to 24 h at 35°C
in ambient air before being examined. The MIC interpretive
criteria for use with HTM broth and this microdilution
method are the same as the MIC correlates for disk diffusion
tests with HTM (Table 1).
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TABLE 1. Interpretive criteria for susceptibility tests performed with Haemophilus speciesa
Disk Zone diam (mm) MIC correlate (,ug/ml)
Antimicrobial agent content
(,ug) Resistant Intermediate Susceptible Resistant Susceptible
Amoxicillin-clavulanate 20/10 <19 >20 >8.0/4.0 <4.0/2.0
Ampicillin 10 <21 22-24 >25 >4.0 <1.0
Ampicillin-sulbactam 10/10 <19 >20 >4.0/2.0 <2.0/1.0
Aztreonam 30 >26 <2.0
Cefaclor 30 <18 19-23 >24 >32 <8.0
Cefamandole 30 <20 21-23 >24 >16 <4.0
Cefonicid 30 <20 21-23 >24 >16 <4.0
Cefotaxime 30 >26 <2.0
Ceftazidime 30 >26 <2.0
Ceftriaxone 30 >26 <2.0
Ceftizoxime 30 >26 <2.0
Cefuroxime 30 <20 21-23 >24 >16 <4.0
Chloramphenicol 30 <25 26-28 >29 >8.0 <2.0
Ciprofloxacin 5 >21 <1.0
Imipenem 10 >16 <4.0
Rifampin 5 <16 17-19 >20 >4.0 <1.0
Tetracycline 30 <25 26-28 >29 >8.0 <2.0
Trimethoprim- 1.25/23.75 <10 11-15 >16 >4.0b <0.5b
sulfamethoxazole
a These interpretive criteria are applicable only to strains of Haemophilus species when susceptibility tests are performed with HTM by the methods described
in the text.
b Refers to the concentration of trimethoprim; the concentration of sulfamethoxazole is 19-fold higher.
It should be noted that inoculum concentrations lower
than 5 x i0' CFU/ml have been advocated for broth dilution
testing of H. influenzae (47). Use of lower inoculum concen-
trations usually results in decreased MICs. Furthermore, it
is clear that MICs obtained with selected beta-lactam anti-
microbial agents, such as cefaclor, cefamandole, and, to
some extent, cefuroxime and cefonicid, increase consider-
ably, particularly with TEM-1-type ,-lactamase-producing
organisms, when inoculum concentrations are increased to
levels higher than 5 x 105 CFU/ml (8, 44, 66). Evidence
which clearly demonstrates that the results of tests per-
formed with either lower or higher inoculum concentrations
are of greater clinical value is, however, lacking. Further-
more, inoculum sizes of 5 x 105 CFU/ml with broth dilution
procedures are considered standard for quantitative suscep-
tibility tests with other organisms (51).
Recognizing the effect of various inoculum concentrations
on the results of broth dilution susceptibility tests with H.
influenzae, for purposes of standardization it is appropriate
to ascertain at some interval that the final organism concen-
tration in the wells of microdilution trays is indeed the
desired 5 x 105 CFU/ml. Furthermore, it should be under-
stood that the concentration of organism in the initial Hae-
mophilus suspension, even when carefully adjusted to a 0.5
McFarland standard, may vary significantly based on a
variety of factors. Of greatest consequence is the age of the
chocolate agar culture from which the suspension is pre-
pared. For example, suspensions equivalent to a 0.5 McFar-
land standard contain roughly 3 x 108 to 4 x 108 CFU/ml
when prepared from a 16- to 18-h chocolate agar culture,
whereas 24-h growth from chocolate agar plates yields
suspensions of approximately 1 x 108 to 2 x 108 CFU/ml
(Jorgensen, personal communication).
The TEM-1-type ,3-lactamase produced by H. influenzae
is readily detected by use of any of a variety of rapid
13-lactamase assays. These include acidimetric tests (67),
iodometric methods (10), and chromogenic cephalosporin
procedures which utilize either nitrocefin or pyridine-1-azo-
dimethylaniline cephalosporin (PADAC) as a substrate (36,
54). Assuming care is taken when performing these assays,
they all seem to work well (63), although higher false-
negative rates have been observed with iodometric proce-
dures. The TEM-1 enzyme is constitutively produced in
large amounts, it is extracellular, and it has high substrate
affinity for penicillin, ampicillin, and the chromogenic ceph-
alosporins (30). 3-Lactamase-producing strains should be
considered resistant to ampicillin, since the ampicillin MICs
for such strains are .4.0 j,g/ml (21, 23). Indeed, for most
,-lactamase-positive isolates, ampicillin MICs will be .8.0jig/ml (21, 23).
Production of chloramphenicol acetyltransferase (CAT)
can be ascertained by using an inexpensive and simple
70-min colorimetric tube procedure (3). Test reagents are
easily prepared and may be stored in frozen aliquots for
prolonged periods. A commercially available filter disk mod-
ification of this assay (Remel, Lenexa, Kans.) should be
used with caution, since numerous equivocal and falsely
negative results were obtained in a recent evaluation of this
procedure versus stock strains of H. influenzae (20). The
accuracy of the commercial disk CAT test was found to be
greatly increased, however, when the test was applied to
fresh clinical isolates (G. V. Doern, unpublished observa-
tions). CAT-producing strains of H. influenzae should be
considered resistant to chloramphenicol, since chloram-
phenicol MICs for such strains will be .8.0 jig/ml (20, 23).
Laboratory strategies for susceptibility testing of H. influ-
enzae. Because of the high prevalence of TEM-1-type 1-
lactamase-mediated ampicillin resistance (23, 38), all clini-
cally significant isolates of H. influenzae should be tested
immediately with one of the rapid ,-lactamase assays.
f-Lactamase-positive strains can be considered ampicillin
resistant. The meaning of a negative 1-lactamase result must
be interpreted in light of recent reports (4, 43, 55, 60) which
have described clinical isolates of H. influenzae which are
resistant to ampicillin by mechanisms other than production
of a TEM-1-type 13-lactamase (46, 48, 56, 60). However, the
prevalence of such strains appears to be very low. In a 1986
nationwide U.S. surveillance study of antimicrobial resis-
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tance among clinical isolates of H. influenzae, only 2 of 2,250
(<0.1%) 3-lactamase-negative strains demonstrated clear
resistance to ampicillin (23). For this reason, a negative
1-lactamase assay nearly always means that the organism is
susceptible to ampicillin. To wit, there exists little need to
routinely perform ampicillin susceptibility tests directly on
3-lactamase-negative isolates. In those rare instances when
it is determined to be necessary to perform an ampicillin
susceptibility test on a 3-lactamase-negative strain of H.
influenzae, either the disk diffusion or broth microdilution
procedure described above should be used.
Systemic isolates of H. influenzae should be promptly
examined for the production of CAT as an indication of
chloramphenicol activity by using the 70-min tube CAT
assay (3). This recommendation is made despite the low
prevalence of chloramphenicol resistance (i.e., 0.5%) among
clinical isolates of H. influenzae in the United States (22, 23).
The assay is timely, inexpensive, and simple to perform; and
it provides definitive therapeutic information. Organisms
yielding positive results with the tube CAT assay should be
considered resistant to chloramphenicol. As with P-lacta-
mase-negative ampicillin-resistant H. influenzae, chloram-
phenicol-resistant strains which apparently lack the CAT
enzyme have been described (9). Strains of this type are,
however, extremely uncommon (23), and as a result there is
little need to routinely perform chloramphenicol susceptibil-
ity tests on CAT-negative strains. Such strains may be
considered chloramphenicol susceptible. Some laboratories,
however, may choose not to use the tube CAT assay since
this procedure requires in-house preparation and storage of
test reagents. In this case, when a chloramphenicol suscep-
tibility test is determined to be necessary, and then only with
systemic isolates of H. influenzae, a disk diffusion or broth
microdilution test as described above may be performed.
Susceptibility tests with antimicrobial agents other than
ampicillin and chloramphenicol should be performed with
HTM and either the disk diffusion or broth microdilution
method described above. In general, however, there is little
justification or need to test other agents against H. influ-
enzae. Routine susceptibility testing is of little or no value
with antimicrobial agents that are uniformly active (i.e.,
third-generation cephalosporins, imipenem, aztreonam, the
fluoroquinolones, and 1-lactamase-inhibitor combinations
such as amoxicillin-clavulanate and ampicillin-sulbactam),
that are relatively inactive (i.e., erythromycin and the sulfo-
namides), that lack a clinical indication for management of
Haemophilus infections (i.e., tetracycline and penicillins
other than ampicillin and amoxicillin), or for which interpre-
tive criteria for results do not exist (i.e., the combination
erythromycin-sulfisoxazole). Examples of agents for which
susceptibility tests may be of some potential utility include
trimethoprim-sulfamethoxazole and selected cephalosporins
such as cefaclor, cefamandole, and, perhaps, cefuroxime
(19, 22, 23). Routine testing of these agents is probably not
warranted; however, when in individual cases it is deter-
mined to be necessary, testing should be restricted to
isolates of H. influenzae recovered from patients with an
infectious disease for which that particular agent is of
potential therapeutic value.
B. CATARRHALIS
Susceptibility test methods. Quantitative dilution suscepti-
bility tests with B. catarrhalis can be performed with unsup-
plemented Mueller-Hinton medium (26). Inoculum densities
for agar dilution tests should be 104 CFU per spot. For broth
macrotube or microdilution procedures, 5 x 105 CFU/ml is
the desired final concentration of test organism (27). Plates,
tubes, or microdilution trays should be incubated in ambient
air at 35°C for at least 20 to 24 h. With the exception of
penicillin and ampicillin, the MIC interpretive criteria pub-
lished by the NCCLS (51) for use with nonfastidious aerobic
bacteria may also be applied to B. catarrhalis. Based on the
results of a recent investigation in which a large number of
clinical isolates of B. catarrhalis were examined, strains for
which ampicillin MICs were .1.0 ,ug/ml were categorized as
being resistant, strains for which MICs were 0.125 to 0.5 ,ug/
ml were defined as moderately susceptible, and strains for
which ampicillin MICs were .0.06 ,ug/ml were considered
susceptible (26). The same criteria should probably be ap-
plied when interpreting penicillin MICs for B. catarrhalis.
The medium of choice for performing disk diffusion sus-
ceptibility tests with B. catarrhalis is also unsupplemented
Mueller-Hinton agar (26). Inoculum suspensions are pre-
pared and plates are inoculated by the method of the NCCLS
(51). Plates are incubated in ambient air at 35°C for 20 to 24
h. The following zone diameter interpretive criteria have
been advocated for use when testing B. catarrhalis with
penicillin (10-U disks) and ampicillin (10-,ug disks): -29 mm
= susceptible and .28 mm = resistant (42, 55). These
criteria are predicated on studies which demonstrated that
the large majority of P-lactamase-producing strains of B.
catarrhalis show zones of inhibition of .29 mm, whereas
,-lactamase-negative strains show zone sizes of .28 mm
(41, 53).
Recently, alternative zone diameter interpretive criteria
have been proposed for B. catarrhalis (26). Based on a
comparison of zones of inhibition with MICs, the following
categories were defined for disk diffusion tests which use
10-,ug ampicillin disks: -38 mm = susceptible, 20 to 37 mm
= moderately susceptible, and .19 mm = resistant. The
MIC correlates for the susceptible and resistant categories
were .0.06 and -1.0 ,ig/ml, respectively. The results of
ampicillin disk tests could be extrapolated to predictions of
penicillin and amoxicillin activity. The use of the latter zone
diameter interpretive criteria means that some 3-lactamase-
positive strains of B. catarrhalis would be defined as mod-
erately susceptible. This may be justified, however, since
P-lactamase production by this organism does not necessar-
ily correlate with either in vitro or in vivo resistance to
antimicrobial agents such as penicillin, ampicillin, or amoxi-
cillin (see below).
With respect to disk diffusion testing with other antimi-
crobial agents, it appears that NCCLS zone diameter inter-
pretive criteria for amoxicillin-clavulanate, cephalothin,
erythromycin, tetracycline, chloramphenicol, and trimetho-
prim-sulfamethoxazole when tested against nonfastidious
bacteria (51) may also be applied to B. catarrhalis (26). With
cefaclor, a zone diameter of .21 mm, not .18 mm, was
found to define the susceptible category (26). With these
exceptions, zone diameter interpretive criteria of proven
utility for B. catarrhalis do not exist.
The P-lactamase of B. catarrhalis is best detected by use
of either the conventional tube nitrocefin assay or its disk
modification (Cefinase disks; BBL Microbiology Systems)
(28). Tube or disk acidimetric assays, iodometric tests, and
procedures which utilize the chromogenic cephalosporin
PADAC as a substrate should be used with caution, since
false-negative results may be obtained when B. catarrhalis is
tested (27, 35). This is probably the result of the specific type
of f-lactamase produced by B. catarrhalis. The enzyme is
produced constitutively in small amounts, it remains tightly
VOL. 32, 1988
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cell associated, and it has a high substrate affinity for
nitrocefin (31, 39).
Laboratory approach to susceptibility testing. A high per-
centage of clinically significant isolates of B. catarrhalis
produce ,-lactamase (18). As a result, this organism when
recovered in the laboratory should probably be examined for
,-lactamase production as an indication of the activity of
penicillin, ampicillin, and amoxicillin. It should be recog-
nized, however, that penicillin, ampicillin, and amoxicillin
have variable activity for ,B-lactamase-producing strains of
B. catarrhalis. While MICs for most strains would be
interpreted as indicating resistance, for at least some 1-
lactamase-producing strains MICs of these agents are 0.6 to
1.0 ,ug/ml (17, 27, 28, 64, 65). MICs of this low magnitude
imply susceptibility. There have also been several reports of
patients with infections presumably caused by ,B-lactamase-
producing strains of B. catarrhalis who have responded
when treated with penicillin, ampicillin, or amoxicillin (24,
34, 40). In other words, 3-lactamase production may not
always translate into either in vitro or in vivo resistance. The
same concern applies to penicillin and ampicillin disk diffu-
sion susceptibility testing with B. catarrhalis when a zone
diameter of .28 mm is used to define resistance. Perfor-
mance of a dilution susceptibility test or use of the alterna-
tive disk diffusion zone diameter interpretive criteria de-
scribed above would eliminate this problem.
A large number of oral and parenteral antimicrobial agents
are uniformly active against B. catarrhalis (1, 25, 29, 62, 65).
These include erythromycin, tetracycline, chloramphenicol,
trimethoprim-sulfamethoxazole, cephalosporins, extended-
spectrum penicillins, imipenem, aztreonam, the fluoroquino-
lones, and the aminoglycosides. Resistance to these agents
in the United States has not been described. In contrast,
clindamycin, vancomycin, and trimethoprim (alone) are uni-
formly inactive. The isoxazoly-penicillins have variable ac-
tivity.
In vitro susceptibility tests can be performed with these
agents by use of quantitative dilution tests or, in selected
instances (see above), by using a disk diffusion procedure.
Again, the appropriateness of routinely performing suscep-
tibility tests with antimicrobial agents of known activity (or
lack of activity) is questionable. In conclusion, routine in
vitro susceptibility testing of B.catarrhalis may not be nec-
essary. With this organism, laboratory efforts should be
directed at providing accurate diagnostic information as
expeditiously as possible. Correct therapeutic decisions do
not require knowledge of the in vitro susceptibility test
results obtained with an individual patient isolate.
N. GONORRHOEAE
Susceptibility test methods. Clinical isolates of N. gonor-
rhoeae have become increasingly resistant to the primary
therapeutic drugs during the last 40 years (2, 6, 16, 33, 45, 49,
57-59). For instance, by the early 1970s, penicillin and
tetracycline MICs for significant numbers of strains were as
high as 0.25 to 1.0 FLg/ml (33, 45, 57, 59). Similarly, elevated
MICs and, in some cases, resistance to the macrolides,
aminoglycosides, and sulfonamides were reported (2, 11, 49,
58). The susceptibility test method used for isolates of N.
gonorrhoeae was primarily the agar dilution procedure,
although several early studies indicated that the disk diffu-
sion method could be reliably used to detect increased MICs
of penicillins, tetracyclines, and other drugs with gonococci
(42, 57, 59). In 1978, Biddle et al. described the results of
MIC-disk diffusion correlation studies with penicillinase-
producing and spectinomycin-resistant strains of N. gonor-
rhoeae (7). An acceptable correlation was achieved by using
agar dilution MICs determined on supplemented Proteose
Peptone agar no. 3 (Difco Laboratories) and disk diffusion
zone diameters determined on GC agar base supplemented
with 1% IsoVitaleX. The results of this investigation and
several more-recent studies conducted at the Centers for
Disease Control (6, 7) have led to the current NCCLS
recommendations for testing gonococci (50, 51).
Agar dilution tests of N. gonorrhoeae with agents other
than trimethoprim and the sulfonamides should be per-
formed with Proteose Peptone agar no. 3 supplemented with
1% hemoglobin and 1% Kellogg's supplement (51; C.
Thornsberry, J. M. Swenson, C. N. Baker, L. K. Mc-
Dougal, S. A. Stocker, and B. C. Hill, Antimicrob. Newsl.
4:47-55, 1987). A different medium, free of inhibitors of
trimethoprim and the sulfonamides, must be used when
testing these agents. This medium consists of Oxoid Diag-
nostic Sensitivity Test agar containing 5% lysed horse blood
and 1% Kellogg's supplement (51; Thornsberry et al., Anti-
microb. Newsl. 4:47-55, 1987). The inoculum size for agar
dilution tests with N. gonorrhoeae is 103 CFU/ml, 10-fold
lower than that recommended for use when testing other
organisms by this method (51). Agar dilution plates are
incubated in 5% CO2 for 20 to 24 h at 35°C.
Broth dilution procedures have been relatively unsuccess-
ful as means for determining MICs with N. gonorrhoeae
principally because of organism autolysis. However, broth
media that avoid this problem have been formulated, thus
enabling the use of broth-based procedures for manual and
automated MIC determinations (32, 61; Y. A. Jeanlouis,
R. J. Rice, and G. G. Goodwin, Program Abstr. 26th Inter-
sci. Conf. Antimicrob. Agents Chemother., abstr. no. 138,
1986). These broth microdilution tests, which employ Pro-
teose Peptone broth no. 3 supplemented with 1% IsoVita-
leX, produced results comparable to those obtained with the
NCCLS agar dilution procedure for the penicillins, doxycy-
cline, erythromycin, spectinomycin, and the quinolones
(61). It should be noted, however, that some newer antimi-
crobial agents, such as imipenem, can be adversely affected
by IsoVitaleX and other medium supplements (data on file,
Merck & Co., Inc.).
Disk diffusion tests with N. gonorrhoeae have been de-
veloped and standardized only for penicillin (50; Thorns-
berry et al., Antimicrob. Newsl. 4:47-55, 1987) and specti-
nomycin (Thornsberry et al., Antimicrob. Newsl.). The
preferred medium consists of GC agar base supplemented
with 1% IsoVitaleX. The conditions of incubation are those
described above for the agar dilution procedure. The
NCCLS zone diameter interpretive criteria for penicillin
(10-U disks) are -20 mm = susceptible and .19 mm =
resistant; for spectinomycin (100-p.g disks), the criteria are
.18 mm = susceptible and .14 mm = resistant. Use of the
aforementioned penicillin criteria effectively categorizes ,B-
lactamase-producing strains of N. gonorrhoeae (PPNG) as
being resistant since PPNG typically shows zone sizes of
.19 mm. These criteria, however, may fail to identify strains
with chromosomally mediated penicillin resistance (i.e., N.
gonorrhoeae strains that are resistant to penicillin but lack a
TEM-1-type 3-lactamase). For these reasons, the Centers
for Disease Control Sexually Transmitted Disease Labora-
tory recommends that zone sizes of <25 mm be considered
resistant (12, 16). There exist no published data to corrobo-
rate this recommendation.
It should be noted that a collaborative study designed to
standardize N. gonorrhoeae susceptibility test methods for
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penicillin, tetracycline, spectinomycin, and ceftriaxone is
now under way (R. N. Jones, personal observations). Qual-
ity assurance and medium performance guidelines will be
developed for agar dilution and disk diffusion methods using
GC agar base supplemented with 1% IsoVitaleX. A quality
control strain(s) of N. gonorrhoeae will be selected, and
medium performance limits will be established. The pro-
posed inoculum will be consistent with other NCCLS stan-
dard procedures (50, 51). The incubation period will be 24 h
in 5 to 7% CO2 or in a candle jar. Regression-line studies
with these four drugs are also forthcoming, thus widening
the number of antibiotics with well-established interpretive
guidelines.
1-Lactamase testing of all N. gonorrhoeae isolates has
been advocated by the Centers for Disease Control and other
agencies as the first level of recognition and control of PPNG
(11, 13-16). Various ,-lactamase test methods can be used to
detect the TEM-type, plasmid-mediated enzyme produced
by gonococcal strains. Nearly comparable levels of accuracy
can be achieved by using the acidimetric, chromogenic
cephalosporin, and iodometric techniques.
Laboratory testing of N. gonorrhoeae. A f-lactamase test
should be performed on all N. gonorrhoeae isolates, even in
PPNG-nonendemic geographic areas. This can be achieved
most economically by using freshly prepared laboratory
reagents (in acidimetric or iodometric tests), although sev-
eral commercial products have proven to be highly reliable.
A negative P-lactamase test result does not always assure a
favorable clinical response to penicillin or ampicillin therapy
because of the increasing prevalence of high-grade, chromo-
somal, non-enzyme-mediated resistance (12, 16, 58). Detec-
tion of penicillin or ampicillin resistance among chromoso-
mally mediated penicillin-resistant strains requires the use of
direct susceptibility tests with these agents. However, given
the relatively low prevalence of such strains, there is prob-
ably no need to routinely examine primary isolates which are
1-lactamase negative with a penicillin or ampicillin suscep-
tibility test. Such testing should, however, be performed on
3-lactamase-negative posttreatment isolates of N. gonor-
rhoeae from patients who failed to respond to penicillin or
ampicillin therapy.
Similarly, routine agar dilution or disk diffusion suscepti-
bility testing of N. gonorrhoeae with alternative therapeutic
agents (i.e., tetracycline, spectinomycin, and cephalosporins
such as cefoxitin, cefotaxime, and ceftriaxone) is not advo-
cated, at least in general clinical microbiology laboratories.
First of all, as stated above, with the exception of specti-
nomycin, susceptibility test procedures with these agents
and N. gonorrhoeae have not been rigorously standardized.
Secondly, resistance with these agents is uncommon. In
general laboratories, testing of these antimicrobial agents
should probably be restricted to isolates of N. gonorrhoeae
obtained from patients known to have failed on therapy.
Spectinomycin may be tested with either the disk diffusion
or agar dilution procedure described above. The other agents
should be tested with the agar dilution procedure.
In conclusion, routine antimicrobial susceptibility testing
of N. gonorrhoeae other than performance of a ,-lactamase
assay should be restricted to public health laboratories,
laboratories that service very active sexually transmitted
disease clinics, and laboratories involved in epidemiologic
investigations.
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